Tizanidine
Hepatic or renal insufficiency. Children, elderly, pregnancy and lactation. Monitor LFT regularly. Stop treatment if liver enzymes are raised persistently >3 times upper limit of normal range. Avoid abrupt withdrawal of therapy. Lactation: May be excreted in breast milk due to lipophilic nature; use caution
Spasticity, Painful muscle spasm
Severe hepatic dysfunction.
N/A
>10% Dry mouth (46-50%),Somnolence (46-50%),Dizziness (16-20%),Asthenia (10-45%) 1-10% Blurred vision (3%),Constipation (4%),Infection (6%),LFT abnormalities (3-5%),Speech disorder (3%),Vomiting (3%),Urinary frequency (3%),UTI (10%) Frequency Not Defined Asthenia,Bradycardia,Hypotension,Orthostatic hypotension,Syncope (rare) Potentially Fatal: Hepatitis.
Tizanidine, an alpha2-adrenergic agonist, is a centrally acting muscle relaxant structurally related to clonidine. It reduces spasticity by increasing presynaptic inhibition of motor neurons and has no direct effect on skeletal muscle, the neuromuscular junction or on monosynaptic spinal reflexes.
Potentiates hypotensive effect of antihypertensives. Increased CNS effects with alcohol and CNS depressants. Increased bradycardia with ?-blockers and digoxin. Increased serum concentration of tizanidine with CYP1A2 inhibitors e.g. zileuton, ciprofloxacin and other fluoroquinolones, antiarrhythmics, cimetidine, famotidine, oral contraceptives, aciclovir and ticlopidine. Decreased serum concentrations of tizanidine with rifampicin. Use with caution with drugs that may prolong QT interval.
Pregnancy category: C Lactation: May be excreted in breast milk due to lipophilic nature; use caution
Oral Muscle Spasticity Spasticity associated with multiple sclerosis and spinal cord injury Initial: 2 mg q6-8hr; no more than 3 doses q24hr Maintenance: Increase by 2 to 4 mg until satisfactory response is achieved with minimum 1-4 days between dose increments Not to exceed 36 mg/day Painful muscle spasm associated with musculoskeletal conditions Adult: 2-4 mg tid. Elderly: Not recommended. Hepatic impairment: Avoid or use with extreme caution.
Child < 18 years: Not recommended
Renal impairment: CrCl (ml/min) Dosage Recommendation <25 Initially, 2 mg once daily, gradually increasing the dose before increasing the frequency of admin.
N/A
The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.